Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize

Tumor Radiosensitization by Monomethyl Auristatin E: Mechanism of Action and Targeted Delivery

(2015) L. Buckel et al.   CANCER RESEARCH

Controversies in the Treatment of Local and Locally Advanced Gastric and Esophageal Cancers

(2015) Deirdre J. Cohen et al.   JOURNAL OF CLINICAL ONCOLOGY

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

(2015) Jeffrey D Bradley et al.   LANCET ONCOLOGY

Exploring mechanisms of acquired resistance to HER2 (human epidermal growth factor receptor 2)-targeted therapies in breast cancer

(2014) Helen Creedon et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials

(2014) Pernelle Lavaud et al.   BMC Medicine

AXL Mediates Resistance to Cetuximab Therapy

(2014) T. M. Brand et al.   CANCER RESEARCH

Interaction of Radiation Therapy With Molecular Targeted Agents

(2014) Zachary S. Morris et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Stage III to IV Head and Neck Carcinoma: RTOG 0522

(2014) K. Kian Ang et al.   JOURNAL OF CLINICAL ONCOLOGY

Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates

(2014) Robert P Lyon et al.   NATURE BIOTECHNOLOGY

Lessons Learned from Radiation Oncology Clinical Trials

(2013) F.-F. Liu et al.   CLINICAL CANCER RESEARCH

Advancing Antibody Drug Conjugation

(2013) Nicole M. Okeley et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy

(2013) Steven H. Lin et al.   JNCI-Journal of the National Cancer Institute

Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques

(2013) Daniel Ayoub et al.   mAbs

Maturing antibody–drug conjugate pipeline hits 30

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Strategies for optimizing the response of cancer and normal tissues to radiation

(2013) Everett J. Moding et al.   NATURE REVIEWS DRUG DISCOVERY

Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma

(2013) Jessica Ley et al.   ONCOLOGY

Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells

(2013) Mohammad Saki et al.   RADIOTHERAPY AND ONCOLOGY

New Paradigms and Future Challenges in Radiation Oncology: An Update of Biological Targets and Technology

(2013) S. L. Liauw et al.   Science Translational Medicine

Radiation Therapy as a Backbone of Treatment of Locally Advanced Non-Small Cell Lung Cancer

(2013) Aaron M. Laine et al.   SEMINARS IN ONCOLOGY

Targeted drugs in combination with radiotherapy for the treatment of solid tumors: current state and future developments

(2013) Edgar Selzer et al.   Expert Review of Clinical Pharmacology

Antibody-Drug Conjugates in Cancer Therapy

(2012) Eric L. Sievers et al.   Annual Review of Medicine

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

(2012) Sandhya Girish et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

DNA damage response and repair: insights into strategies for radiation sensitization of gliomas

(2011) Santosh Kesari et al.   Future Oncology

Targeting the human EGFR family in esophagogastric cancer

(2011) Alicia Okines et al.   Nature Reviews Clinical Oncology

Targeting HER2 signaling pathway for radiosensitization: Alternative strategy for therapeutic resistance

(2010) Mina No et al.   CANCER BIOLOGY & THERAPY

Challenges of integrating chemotherapy and targeted therapy with radiation in locally advanced head and neck squamous cell cancer

(2010) Shanthi Marur et al.   CURRENT OPINION IN ONCOLOGY

Concurrent Cisplatin and Radiation Versus Cetuximab and Radiation for Locally Advanced Head-and-Neck Cancer

(2010) Lawrence Koutcher et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Understanding resistance to EGFR inhibitors—impact on future treatment strategies

(2010) Deric L. Wheeler et al.   Nature Reviews Clinical Oncology

Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab

(2009) Carola W. N. Damen et al.   JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY

Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

(2009) James A Bonner et al.   LANCET ONCOLOGY